Temozolomide and AGAT Inactivation in Cancer Treatment
Author Information
Author(s): Tolcher A W, Gerson S L, Denis L, Geyer C, Hammond L A, Patnaik A, Goetz A D, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler D L, Rowinsky E K
Primary Institution: Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
Hypothesis
Frequent temozolomide treatment may lead to significant inactivation of O6-alkylguanine-DNA alkyltransferase (AGAT), enhancing its anticancer effects.
Conclusion
The study found that protracted low-dose temozolomide schedules resulted in significant and sustained inactivation of AGAT in patients.
Supporting Evidence
- Temozolomide showed a 47% response rate in patients with recurrent glioblastoma multiforme on a protracted schedule.
- AGAT activity decreased by 72% after 7 days of daily temozolomide treatment.
- Patients treated at maximum tolerated doses showed an 80.1% decrease in AGAT activity after 7 days.
Takeaway
This study shows that giving a cancer drug called temozolomide more often can make it work better by stopping a protein that helps cancer cells fix themselves.
Methodology
Patients with solid tumors received temozolomide on two different schedules, and AGAT activity was measured in their blood cells.
Limitations
The study was limited by the small number of patients who experienced severe thrombocytopenia, which may affect the generalizability of the findings.
Participant Demographics
Patients with solid malignancies refractory to standard therapy, aged 18 and older.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website